Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 5,699 |
|
|||||
| News | - | ||||||
| Day High | 1.1299 | Low High |
|||||
| Day Low | 1.10 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| NanoViricides Inc | NNVC | AMEX | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.01 | -0.90% | 1.10 | 17:30:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1.10 | 1.10 | 1.1299 | 1.10 | 1.11 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 50 | 5,699 | US$ 1.10 | US$ 6,292 | - | 1.00 - 2.00 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 17:30:00 | 100 | US$ 1.10 | USD |
NanoViricides Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 12.96M | 11.78M | - | 0 | -8.59M | -0.73 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
NanoViricides News
| Date | Time | Source | News Article |
|---|---|---|---|
| 2/16/2024 | 15:53 | Edgar (US Regulatory) | Form 8-K - Current report |
| 2/14/2024 | 15:55 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 1/19/2024 | 15:44 | Edgar (US Regulatory) | Form 8-K - Current report |
| 12/04/2023 | 15:08 | Edgar (US Regulatory) | Form DEF 14A - Other definitive proxy statements |
| 10/13/2023 | 15:30 | Edgar (US Regulatory) | Form 10-K - Annual report [Section 13 and 15(d), not S-K.. |
| 9/28/2023 | 15:44 | Edgar (US Regulatory) | Form NT 10-K - Notification of inability to timely file Form.. |
| 9/01/2023 | 15:46 | Edgar (US Regulatory) | Form 8-K - Current report |
| 7/06/2023 | 10:16 | InvestorsHub NewsWire | Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is.. |
| 5/04/2023 | 05:45 | GlobeNewswire Inc. | NanoViricides, Inc. to Present at The Inaugural Ef Hutton.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical NNVC Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.19 | 1.28 | 1.0297 | 1.12 | 17,793 | -0.09 | -7.56% |
| 1 Month | 1.15 | 1.50 | 1.0297 | 1.28 | 36,725 | -0.05 | -4.35% |
| 3 Months | 1.14 | 1.50 | 1.0297 | 1.23 | 29,851 | -0.04 | -3.51% |
| 6 Months | 1.21 | 1.50 | 1.00 | 1.18 | 39,755 | -0.11 | -9.09% |
| 1 Year | 1.30 | 2.00 | 1.00 | 1.34 | 51,473 | -0.20 | -15.38% |
| 3 Years | 4.20 | 7.86 | 1.00 | 4.82 | 337,919 | -3.10 | -73.81% |
| 5 Years | 0.27 | 19.80 | 0.16045 | 7.11 | 685,289 | 0.83 | 307.41% |
NanoViricides Description
| Nanoviricides Inc is a nano-biopharmaceutical company which is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through an in-licensing strategy. |
